Loading
Datar Cancer Genetics' blood test that looks for clumps of tumour cells, sold privately in the UK; the developer's marketing figures go beyond what its own papers report.
Datar Cancer Genetics runs the test in laboratories in Nashik, India, and Guildford, UK. In the company-authored Gaya et al. (Cancer Cytopathology 2021), C-ETACs were found in 91.8% of 9,416 people with known cancer and 92.6% of 6,025 symptomatic people diagnosed with cancer, and were undetectable in 96.3% of 13,919 asymptomatic people, meaning about 3.7% tested positive; staining matched histology in 93.1% of a subset. Akolkar et al. (International Journal of Cancer 2020) reported detection in 89.8% of 5,509 cancers and in 3% of 8,493 people with no abnormal findings.
Datar's 2022 Trucheck Intelli brochure claims detection of over 70 solid cancer types, detection of the cancers it screens for 95% of the time, and false positives in around 1% of cases, citing Gaya 2021; that paper's abstract reports neither the 95% nor the 1% figure. No stage I sensitivity has been published, and no peer-reviewed screening-population positive predictive value. A UK reseller lists it at £1,105 plus an £89 GP consultation (Midland Health); that is a reseller's price. CE marking is stated by resellers but was not confirmed from a primary source, and no MHRA, CDSCO or FDA status was found.
Harvests circulating ensembles of tumour-associated cells (C-ETACs) from blood and profiles them with organ-specific antibody stains to suggest an organ of origin.
1.Trucheck Intelli slips into a pocket on its target.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United Kingdom | - | £1,105 plus £89 GP consultation (reseller Midland Health, not Datar) | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Trucheck Intelli" OR ABSTRACT:"Trucheck Intelli" OR TITLE:"Trucheck" OR ABSTRACT:"Trucheck" OR TITLE:"TruCheck" OR ABSTRACT:"TruCheck") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Trucheck Intelli, not a curated reading list.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/